CEO Nils Brünner comments: "The grant of patents for WntResearch's lead compound Foxy-5 in China, Australia and Japan is very satisfactory and in line with the IP-strategy for Foxy-5. The granting is an important step towards development and commercialization. It is a pre-requisite for partner negotiations and supports that FOXY-5 as an anti-metastatic drug is a new and innovative concept." For further information please contact: Nils Brünner, CEO E-mail: nbr@wntresearch.com Telephone: +45 2614 4708